OneMedNet Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$ONMD
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Get the next $ONMD alert in real time by email
false 0001849380 0001849380 2025-03-12 2025-03-12 0001849380 ONMD:CommonStock0.0001ParValuePerShareMember 2025-03-12 2025-03-12 0001849380 ONMD:RedeemableWarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2025-03-12 2025-03-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 12, 2025

 

ONEMEDNET CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware   001-40386   86-2076743

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

6385 Old Shady Oak Road, Suite 250

Eden Prairie, MN 55344

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: 800-918-7189

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   ONMD   The Nasdaq Stock Market LLC
         
Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share   ONMDW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On March 12, 2025, OneMedNet Corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 31 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2). The Staff also noted that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum stockholders’ equity of $2.5 million, and Nasdaq Listing Rule 5550(b)(3), which requires listed companies to maintain a minimum of $500,000 of net income from continuing operations. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on Nasdaq.

 

In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days, or until September 8, 2025 (the “Compliance Period”), to regain compliance with the MVLS requirement. The regain compliance, the Company’s MVLS must close at or above $35 million for a minimum of ten consecutive business days during the Compliance Period. If the Company does not regain compliance by the end of the Compliance Period, the Staff will provide written notice to the Company that its securities are subject to delisting. At that time, the Company may appeal any such delisting determination to a hearings panel.

 

The Company intends to actively monitor the Company’s MVLS, and may, if appropriate, evaluate available options to resolve the deficiency and regain compliance with the MVLS requirement. While the Company is exercising diligent efforts to maintain the listing of its securities on Nasdaq, there can be no assurance that the Company will be able to regain or maintain compliance with Nasdaq listing standards.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 14, 2025

 

  ONEMEDNET CORPORATION
     
  By: /s/ Aaron Green
    Aaron Green
    Chief Executive Officer

 

 

 

Get the next $ONMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ONMD

DatePrice TargetRatingAnalyst
More analyst ratings

$ONMD
Press Releases

Fastest customizable press release news feed in the world

See more
  • 31 Million Patient Journeys, One Mission

    MINNEAPOLIS, March 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet, an AI-powered Real World Data leader, has announced a collaboration with Datavant, a health data platform, to provide access to tokenized, purpose-built data for life sciences and medical research through Datavant's health data ecosystem. Leveraging OneMedNet's network of 31M patients, 121M+ clinical studies—EMR insights like images, ECGs, and notes—this collaboration enables life sciences companies to integrate claims data for a full view of patient journeys tailored to specific diseases. By integrating OneMedNet's patient tokens into the Datavant ecosystem of more than 300 real-world data partners, customers seeking Real-World D

    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • Dr. Kenneth Alleyne Joins OneMedNet Board of Directors

    MINNEAPOLIS, March 03, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet"), the leading Real World Data platform powered by AI-driven de-identification, announces the appointment of Dr. Kenneth Alleyne to its Board of Directors. A board-certified orthopedic surgeon specializing in sports medicine, Dr. Alleyne will assume the role of Chair of the Audit Committee, bringing extensive expertise in healthcare, insurance, investment, and corporate governance to the organization. Dr. Alleyne is the managing partner of HartHaven Partners, a healthcare consulting firm supporting private equity and venture capital firms. He co-founded NextLevel Health Partners and Zing Health

    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • OneMedNet Regains Compliance with NASDAQ Listing Requirements

    MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data ("iRWD™"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(b)(2) (the "Rule") after the market value of the Company's common stock exceeded $35,000,000 for 10 consecutive business days. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") confirming compliance with the Rule.   As a result,

    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$ONMD
SEC Filings

See more

$ONMD
Leadership Updates

Live Leadership Updates

See more
  • Dr. Kenneth Alleyne Joins OneMedNet Board of Directors

    MINNEAPOLIS, March 03, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet"), the leading Real World Data platform powered by AI-driven de-identification, announces the appointment of Dr. Kenneth Alleyne to its Board of Directors. A board-certified orthopedic surgeon specializing in sports medicine, Dr. Alleyne will assume the role of Chair of the Audit Committee, bringing extensive expertise in healthcare, insurance, investment, and corporate governance to the organization. Dr. Alleyne is the managing partner of HartHaven Partners, a healthcare consulting firm supporting private equity and venture capital firms. He co-founded NextLevel Health Partners and Zing Health

    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • OneMedNet Announces Exciting New Collaboration with Bayer's AI Innovation Platform to Help Accelerate Healthcare AI Development

    MINNEAPOLIS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), a Real-World Data (RWD) platform — has announced its collaboration with Bayer's AI Innovation Platform (AIIP). By joining AIIP, the partnership aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products. "We are thrilled to join forces with Bayer's AI Innovation Platform," said Aaron Green, CEO & President of OneMedNet. "This collaboration allows us to combine our regulatory-grade real-world data platform, which aggregates data from our provider network of over 1,400 healthcare

    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • OneMedNet appoints new CFO

    MINNEAPOLIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Real World Data (RWD), has announced that Bob Golden has joined the OneMedNet Executive Team as Chief Financial Officer spearheading all aspects of the company's financial and accounting operations while continuing to serve as a member of the Board of Directors. Mr. Golden is a Certified Public Accountant with more than 40 years of experience. Mr. Golden has served as the Managing Partner of Cohen, Bender & Golden LLP since 2015, where he provides consulting, accounting and tax services to middle market businesses and owners. Mr. Golde

    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$ONMD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more